Ablynx has announced its open recruitment for the first-in-infant study with ALX-0171, a nanobody developed for the treatment of RSV infections.
The Phase IIa study is a multi-centre, multi-country trial to evaluate the safety, tolerability and clinical activity (including effect on feeding, respiratory rate, wheezing, coughing and general appearance) of ALX-0171, administered via inhalation, in otherwise healthy infants and toddlers (aged 5-24 months) diagnosed with RSV and hospitalised for a lower respiratory tract infection. The study will be run in five European countries with potential additional sites available in the Southern Hemisphere as risk mitigation for the unpredictable length and severity of the European RSV season.
